SELLAS develops cancer immunotherapy and targeted drug candidates for blood cancers and solid tumors. SLS reports earnings on Wed, Nov 18, 2026. Over the past 90 days StreetAlpha recorded 6 whale options trades in SLS, 50% of them bullish and 50% bearish. In the past 30 days there were 3 dark pool prints.
Earnings
Earnings calendar →Whale Options Flow
90DNo whale options trades in SLS in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SLS is in one of them and how their past SLS trades turned out.
SLS News Tone and Price
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SLS in an article yet. Here's the latest on the wider market.
About SELLAS Life Sciences Group
SELLAS is a clinical stage biopharmaceutical company based in New York that develops treatments for cancer. Its lead candidate, galinpepimut-S, is an immunotherapy that targets the WT1 protein, which is found in many types of cancer, including blood cancers such as acute myeloid leukemia. The company is also developing tambiciclib, a small molecule drug that inhibits CDK9, for patients with blood and solid cancers. Both candidates are in clinical trials.
- Headquarters
- New York, NY
- Founded
- 2006
- Website
- galenabiopharma.com ↗